141st APHA Annual Meeting and Exposition

Home Events & Meetings Annual Meeting Schedule & Program

Recorded Annual Meeting Presentations (RAMP) are now available for purchase.
Only $90 for presenters, $140 for registered attendees and $200 for non-attendees.

Online Program

285976
Survival of women with triple negative breast cancer in Florida


Sunday, November 3, 2013

Hong Xiao, PhD, Econominc, Social & Administrative Pharmacy, Florida A&M University, Tallahassee, FL
Fei Tan, PhD, Mathematical Sciences, Indiana University-Purdue University Indianapolis, Indianapolis, IN
Lenonidas Koniaris, MD, Thomas Jefferson University Hospital, Philadelphia, PA
Georges Adunlin, MA, Division of Economic, Social and Administrative Pharmacy, Florida A&M University, Tallahassee, FL
Askal Ali, MA, Econominc, Social & Administrative Pharmacy, Florida A&M University, Tallahassee, FL
Sriharsha Gummadi, BS, Department of Surgery, Jefferson Medical College, Philadelphia, PA
Jason Feldman, MPH, Bureau of Epidemiology, Florida Department of Health, Tallahassee, FL
Youjie Huang, MD, DrPH, Bureau of Epidemiology, Florida Department of Health, Tallahassee, FL
Background: Tumor markers are becoming increasingly important in breast cancer (BCa) research because of their impact on prognosis, treatment, and survival. Purpose: To determine the impact of hormone receptor status and HER2 on BCa survival.

Methods: Electronic medical records from a network of 9 hospitals were linked to female BCa patients diagnosed between 2007 and 2010 in Florida. Cox proportional hazards model was used.

Results: Two-year survival of the study population was 95.1%. Median follow-up time for those who died due to BCa was 569 days. Survival functions between blacks and non-blacks were significantly different over time (p < 0.0001). Survival probability among blacks was lower than that of non-blacks. Hazard of BCa death among patients with triple negative (TN) and patients with unknown status were 4.34 and 2.35 times that of non-TN patients. Death rate among blacks was 1.6 times that of non-blacks. Other factors associated with increased hazard were: being diagnosed in regional stage or having unknown diagnosis stage, single, Medicare user, having poorly or un-differentiated tumor, with larger tumor size, and more positive nodes detected. Immediately after diagnosis, distant stage and more comorbidity conditions were associated with an elevated risk, and more lymph nodes examined was associated with reduced risk of BCa death. But these effects gradually attenuated over time.

Conclusions: Women with triple negative BCa have the worst survival outcome. This study highlights the importance of improvement of care for patients with TN biomarkers.

Learning Areas:

Chronic disease management and prevention
Public health or related research

Learning Objectives:
Discuss the role of hormone receptor status and HER2 in survival among women with breast cancer

Keyword(s): Women's Health, Cancer

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: I am a co-investigator for the Expansion Research Capability to Study Comparative Effectiveness in Complex Patients project.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.

Back to: 2047.0: Innovative research on cancer prevention and control among women: Confronting and eliminating disparities (a joint session of the Cancer Forum and Women’s Caucus)